Cocrystal Pharma, Inc.
COCP
$1.55
$0.0050.33%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -50.63% | -22.97% | -17.35% | 4.07% | 13.36% |
| Gross Profit | 50.63% | 22.97% | 17.35% | -4.07% | -13.36% |
| SG&A Expenses | -11.37% | -14.68% | -10.83% | -4.46% | -3.17% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -40.32% | -20.51% | -15.51% | 1.60% | 8.50% |
| Operating Income | 40.32% | 20.51% | 15.51% | -1.60% | -8.50% |
| Income Before Tax | 29.94% | 5.38% | 2.67% | -3.78% | 8.32% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 29.94% | 5.38% | 2.67% | -3.78% | 8.32% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 29.94% | 5.38% | 2.67% | -3.78% | 8.32% |
| EBIT | 40.32% | 20.51% | 15.51% | -1.60% | -8.50% |
| EBITDA | 40.36% | 20.40% | 15.35% | -1.91% | -8.73% |
| EPS Basic | 29.88% | 5.56% | 9.35% | 8.83% | 23.57% |
| Normalized Basic EPS | 38.77% | 18.23% | 20.12% | 10.95% | 12.49% |
| EPS Diluted | 29.88% | 5.56% | 9.49% | 8.95% | 23.66% |
| Normalized Diluted EPS | 38.77% | 18.23% | 20.12% | 10.95% | 12.49% |
| Average Basic Shares Outstanding | -0.06% | 0.20% | 5.48% | 11.61% | 18.06% |
| Average Diluted Shares Outstanding | -0.06% | 0.20% | 5.48% | 11.61% | 18.06% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |